21-Gene Assay in Early Breast Cancer
Genomic Health, a life science company in California, offers Oncotype DX testing. This 21-gene assay provides prediction of chemotherapy benefit for breast cancer patients, as well as recurrence. Validated, the test allows physicians and patients to make more informed treatment decisions. However, the test only applies to patients with certain cancer characteristics. According to the Mayo Clinic, this limits the test's usefulness, as it applies to only a small number of patients.